Tag: Australia

Australia's listed cannabis sector has become increasingly difficult to define simply as "cannabis". The latest results show companies moving in ...

BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising ...

For decades, psychedelic medicine sat on the margins of psychiatry, constrained by international drug controls, political controversy and the legacy ...

Australia's modern psychedelic medicine story is usually traced to the Therapeutic Goods Administration's 2023 decision to allow authorised psychiatrists to ...

Emyria (ASX: EMD) has cleared a key operational bottleneck across its Perth and Queensland psychedelic-assisted therapy operations, with therapist availability ...

New Zealand is building a small but increasingly active psychedelic medicine sector, with clinical psilocybin access, Māori-led research and a ...

Australia's psychedelic medicine industry has crossed the regulatory threshold. Since 1 July 2023, specifically authorised psychiatrists have been able to ...

As psychedelic-assisted therapy moves from research into clinical practice in Australia, the organisations building the infrastructure around the sector are ...

When Australia became the first country to permit authorised psychiatrists to prescribe MDMA and psilocybin for specific mental health conditions ...

Australian psychedelic biotechnology company Entropy Neurodynamics (ASX: ENP) has secured Human Research Ethics Committee (HREC) approval to begin what it ...